Argenica Therapeutics Ltd has released a press release.
Preliminary Pre-Clinical Tox Studies Successfully Completed
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Argenica to be Granted Patent Protection in the US
- Positive Preclinical Data for ARG-007 Neuroprotection in HIE
- Phase 1 Clinical Trial Overview & Roadmap
- Argenica Partners With Linear For Phase 1 Clinical Trial
- Argenica Achieves Manufacturing Milestones
Later from Argenica Therapeutics
- Successful Completion of Final GLP Genotoxicity Studies
- Peer Reviewed Paper Published on Preclinical Study
- Positive Preclincal Data on Efficacy in New Indication
- Argenica Appoints CEO Dr Liz Dallimore Managing Director
- Maximum Tolerated Dose Successfully Established in Studies
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics